The Leiden Early Arthritis Clinic

Clinical and Experimental Rheumatology

Volumn 21, Issue 5 SUPPL. 31, 2003, Pages

  van Aken, J ^a   van Bilsen, J H M ^a   Allaart, C F ^a   Huizinga, T W J ^a   Breedveld, F C ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Arthritis; Early arthritis clinic; Follow up; Inception cohort

Indexed keywords

ANTIRHEUMATIC AGENT; AUTOANTIBODY; CORTICOSTEROID; CYTOKINE; HLA DQ ANTIGEN; HLA DR4 ANTIGEN; INTERLEUKIN 1; INTERLEUKIN 10; METHOTREXATE; PLACEBO; RHEUMATOID FACTOR; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ANAMNESIS; B LYMPHOCYTE; CLINICAL EXAMINATION; CLINICAL PRACTICE; CYTOKINE PRODUCTION; DATA BASE; DIAGNOSTIC PROCEDURE; DISEASE DURATION; ENVIRONMENTAL FACTOR; FOLLOW UP; GENETIC SUSCEPTIBILITY; HEALTH CARE FACILITY; HEREDITY; HOSPITAL DEPARTMENT; HUMAN; IMMUNOLOGY; JOINT RADIOGRAPHY; LABORATORY TEST; MEDICAL LITERATURE; MEDICAL RESEARCH; MEDICAL SPECIALIST; NETHERLANDS; NURSE; PATHOPHYSIOLOGY; PATIENT CARE; PHYSICAL EXAMINATION; PHYSICIAN; PRIORITY JOURNAL; QUESTIONNAIRE; REVIEW; RHEUMATOID ARTHRITIS; RHEUMATOLOGY; RISK FACTOR; SCORING SYSTEM; SYNOVIOCYTE; T LYMPHOCYTE; UNIVERSITY HOSPITAL; WORK DISABILITY;

AMBULATORY CARE FACILITIES; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; COMBINED MODALITY THERAPY; FEMALE; HUMANS; MALE; NETHERLANDS; OUTCOME ASSESSMENT (HEALTH CARE); PHYSICAL THERAPY MODALITIES; REFERRAL AND CONSULTATION; RHEUMATOLOGY; SEVERITY OF ILLNESS INDEX;

EID: 0142029680     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (44)

1. . SPEYER I, HAZES JM, BREEDVELD FC: Recruitment of patients with early rheumatoid arthritis - The Netherlands experience. J Rheumatol 1996; 44 (Suppl.): 84-5.
2. van der HORST-BRUINSMA I, SPEYER I, VISSER H, BREEDVELD FC, HAZES JM: Diagnosis and course of early-onset arthritis: results of a special early arthritis clinic compared to routine patient care. Br J Rheumatol 1998; 37:1084-8.
3. HUIZINGA TW, MACHOLD KP, BREEDVELD FC, LIPSKY PE, SMOLEN JS: Criteria for early rheumatoid arthritis: from Bayes' law revisited to new thoughts on pathogenesis. Arthritis Rheum 2002; 46: 1155-9.
4. STASTNY P: Association of the B-cell alloantigen DRw4 with rheumatoid arthritis. N Engl J Med 1978; 298: 869-71.
5. OLSEN NJ, CALLAHAN LF, BROOKS RH, et al.: Associations of HLA-DR4 with rheumatoid factor and radiographic severity in rheumatoid arthritis. Am J Med 1988; 84: 257-64.
6. EMERY P, SALMON M, BRADLEY H, et al.: Genetically determined factors as predictors of radiological change in patients with early symmetrical arthritis. BMJ 1992; 305: 1387-9.
7. van ZEBEN D, HAZES JM, ZWINDERMAN AH, et al.: Association of HLA-DR4 with a more progressive disease course in patients with rheumatoid arthritis. Results of a followup study. Arthritis Rheum 1991; 34: 822-30.
8. SUAREZ-ALMAZOR ME, TAO S, MOUSTARAH F, RUSSELL AS, MAKSYMOWYCH W: HLA-DR1, DR4, and DRB1 disease related subtypes in rheumatoid arthritis. Association with susceptibility but not severity in a city wide community based study. J Rheumatol 1995; 22: 2027-33.
9. TELLER K, BUDHAI L, ZHANG M, HARAMATI N, KEISER HD, DAVIDSON A: HLA-DRB1 and DQB typing of Hispanic American patients with rheumatoid arthritis: the "shared epitope" hypothesis may not apply. J Rheumatol 1996; 23: 1363-8.
10. GREGERSEN PK, SILVER J, WINCHESTER RJ: The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum 1987; 30: 1205-13.
11. THOMSON W, HARRISON B, OLLIER B, et al.: Quantifying the exact role of HLA-DRB1 alleles in susceptibility to inflammatory polyarthritis: results from a large, population-based study. Arthritis Rheum 1999; 42:757-62.
12. ZANELLI E, GONZALEZ-GAY MA, DAVID CS: Could HLA-DRB1 be the protective locus in rheumatoid arthritis? Immunol Today 1995; 16: 274-8.
13. ZANELLI E, KRCO CJ, BAISCH JM, CHENG S, DAVID CS: Immune response of HLA-DQ8 transgenic mice to peptides from the third hypervariable region of HLA-DRB1 correlates with predisposition to rheumatoid arthritis. Proc Natl Acad Sci USA 1996; 93: 1814-9.
14. ZANELLI E, KRCO CJ, DAVID CS: Critical residues on HLA-DRB1*0402 HV3 peptide for HLA-DQ8-restricted immunogenicity: implictions for rheumatoid arthritis predisposition. J Immunol 1997; 158: 3545-51.
15. van der HORST-BRUINSMA I, VISSER H, HAZES JM, et al.: HLA-DQ-associated predisposition to and dominant HLA-DR-associated protection against rheumatoid arthritis. Hum Immunol 1999; 60: 152-8.
16. VOS K, van der HORST-BRUINSMA I, HAZES JM, et al.: Evidence for a protective role of the human leukocyte antigen class II region in early rheumatoid arthritis. Rheumatology (Oxford) 2001; 40: 133-9.
17. VOS K, VISSER H, SCHREUDER GM, et al.: Human leukocyte antigen-DQ and DR polymorphisms predict rheumatoid arthritis outcome better than DR alone. Hum Immunol 2001; 62: 1217-25.
18. KAIJZEL EL, van DONGEN H, BAKKER AM, BREEDVELD FC, HUIZINGA TW, VERWEIJ CL: Relationship of polymorphisms of the Interleukin-1 gene cluster to occurrence and severity of rheumatoid arthritis. Tissue Antigens 2002; 59: 122-6.
19. REUSS E, FIMMERS R, KRUGER A, BECKER C, RITTNER C, HOHLER T: Differential regulation of interleukin-10 production by genetic and environmental fact. Genes Immun 2002; 3: 407-13.
20. WESTENDORP RG, LANGERMANS JA, HUIZINGA TW, VERWEIJ CL, STURK A: Genetic influence on cytokine production in meningococcal disease. Lancet 1997; 349: 1912-3.
21. LARD LR, van GAALEN FA, SCHONKEREN JJM, et al.: The -2849G/A IL-10 promoter polymorphism affects joint destruction and autoantibody production in rheumatoid arthritis. Arthritis Rheum 2003; 48: 1841-8.
22. van der HORST-BRUINSMA I, HUIZINGA TW, LAGAAY EM, et al.: The influence of a partially HLA-matched blood transfusion on the disease activity of rheumatoid arthritis. Rheumatology (Oxford) 1999; 38: 53-8.
23. van DUNNÉ FM, LARD LR, ROOK D, HELMERHORST FM, HUIZINGA TW: Miscarriage but not fecundity is associated with progression of joint destruction in rheumatoid arthritis. Submitted for publication.
24. SYMMONS DP, BANKHEAD CR, HARRISON BJ, et al.: Blood transfusion, smoking, and obesity as risk factors for the development of rheumatoid arthritis: results from a primary care-based incident case-control study in Norfolk, England. Arthritis Rheum 1997; 40: 1955-61.
25. HELIOVAARA M, AHO K, AROMAA A, KNEKT P, REUNANEN A: Smoking and risk of rheumatoid arthritis. J Rheumatol 1993; 20:1830-5.
26. UHLIG T, HAGEN KB, KVIEN TK: Current tobacco smoking, formal education, and the risk of rheumatoid arthritis. J Rheumatol 1999; 26: 47-54.
27. LARD LR, HUIZINGA TW, HAZES JM, VLIELAND TP: Delayed referral of female patients with rheumatoid arthritis. J Rheumatol 2001; 28: 2190-2.
28. VAN ZEBEN D, BREEDVELD FC: Prognostic factors in rheumatoid arthritis. J Rheumatol 1996; 44 (Suppl.): 31-3.
29. LARD LR, BOERS M, VERHOEVEN A, et al.: Early and aggressive treatment of rheumatoid arthritis patients affects the association of HLA class II antigens with progression of joint damage. Arthritis Rheum 2002; 46: 899-905.
30. LARD LR, VISSER H, SPEYER I, et al.: Early versus delayed treatment in patients with recent-onset rheumatoid arthritis: comparison of two cohorts who received different treatment strategies. Am J Med 2001; 111: 446-451.
31. van AKEN J, LARD LR, LE CESSIE S, HAZES JM, BREEDVELD FC, HUIZINGA TW: Radiologic outcome after four years of early versus delayed treatment strategy in patients with recent-onset rheumatoid arthritis. Ann Rheum Dis; Accepted for publication.
32. VISSER H, LE CESSIE S, VOS K, BREEDVELD FC, HAZES JM: How to diagnose rheumatoid arthritis early: a prediction model for persistent (erosive) arthritis. Arthritis Rheum 2002; 46: 357-65.
33. Statement on Sarcoidosis: Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. Am J Respir Crit Care Med 1999; 160: 736-55.
34. VISSER H, VOS K, ZANELLI E, et al.: Sarcoid arthritis: clinical characteristics, diagnostic aspects, and risk factors. Ann Rheum Dis 2002; 61: 499-504.
35. SCHELLEKENS GA, VISSER H, de JONG BA, et al.: The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum 2000; 43:155-63.
36. van BOEKEL MA, VOSSENAAR ER, van den HOOGEN FH, van VENROOIJ WJ: Autoantibody systems in rheumatoid arthritis: specificity, sensitivity and diagnostic value. Arthritis Res 2002; 4: 87-93.
37. van GAALEN FA, LINN-RASKER SP, van VENROOIJ WJ, et al.: In undifferentiated arthritis autoantibodies to cyclic citrullinated peptides (CCP) predict progression to rheumatoid arthritis: a prospective cohort study. Submitted for publication.
38. CUNNANE G, FITZGERALD O, BEETON C, CAWSTON TE, BRESNIHAN B: Early joint erosions and serum levels of matrix metalloproteinase 1, matrix metalloproteinase 3, and tissue inhibitor of metalloproteinases 1 in rheumatoid arthritis. Arthritis Rheum 2001; 44: 2263-74.
39. MAEDA S, SAWAI T, UZUKI M, TAKAHASHI Y, OMOTO H, SEKI M et al.: Determination of interstitial collagenase (MMP-1) in patients with rheumatoid arthritis. Ann Rheum Dis 1995; 54: 970-5.
40. TCHETVERIKOV I, LARD LR, DEGROOT J, et al.: Matrix metalloproteinases-3, -8, -9 as markers of disease activity and joint damage progression in early rheumatoid arthritis. Ann Rheum Dis; Accepted for publication.
41. LARD LR, ROEP BO, TOES REM, HUIZINGA TW: Enhanced levels of IL-16 in rheumatoid arthritis patients are associated with joint destruction. J Rheumatol (in press).
42. BARRETT EM, SCOTT DG, WILES NJ, SYMMONS DP: The impact of rheumatoid arthritis on employment status in the early years of disease: a UK community-based study. Rheumatology (Oxford) 2000; 39: 1403-9.
43. MERKESDAL S, RUOF J, SCHOFFSKI O, BERNITT K, ZEIDLER H, MAU W: Indirect medical costs in early rheumatoid arthritis: composition of and changes in indirect costs within the first three years of disease. Arthritis Rheum 2001; 44: 528-34.
44. YOUNG A, DIXEY J, COX N, DAVIES P, DEVLIN J, EMERY P et al.: How does functional disability in early rheumatoid arthritis (RA) affect patients and their lives ? Results of 5 years of follow-up in 732 patients from the Early RA Study (ERAS). Rheumatology (Oxford) 2000; 39: 603-11.